{
"id":"mk19_a_id_s18",
"subspecialtyId":"id",
"title":"HIV/AIDS",
"jsonContent":{
"type":"section",
"id":"mk19_a_id_s18",
"title":{
"__html":"HIV/AIDS"
},
"titleNode":{
"type":"section-title",
"hlId":"c30cc9",
"children":[
"HIV/AIDS"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_id_s18_0",
"children":[
{
"type":"p",
"hlId":"04fbf4",
"children":[
"HIV infection remains a significant global health concern despite being a treatable disease. Many persons living with HIV infection are not aware of their status because they have never been tested; others have been diagnosed but are not receiving care. This chapter will focus on HIV-1. Infection with HIV-2 primarily occurs in parts of Africa and remains rare in the United States; HIV-2 generally is a less progressive disease with less immunocompromise and lower risk of opportunistic infections. Testing for HIV infection detects HIV-1 and HIV-2 antibodies (see Screening and Diagnosis)."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_1",
"title":{
"__html":"Prevention"
},
"titleNode":{
"type":"section-title",
"hlId":"c53b76",
"children":[
"Prevention"
]
},
"children":[
{
"type":"p",
"hlId":"9b23dc",
"children":[
"HIV transmission occurs through sexual contact or exposure to other body fluids ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t60",
"wrapId":"1",
"children":[
"Table 60"
]
}
]
},
")"
]
},
". Reducing transmission can be accomplished by using barrier methods, such as condoms during sexual contact, and through clean syringe services programs (needle exchange programs) for persons who inject drugs. Universal blood donor testing has all but eliminated infection through blood transfusion in the United States, with current risk estimated to be one in 2 million."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_a_id_t60"
]
},
{
"type":"p",
"hlId":"17322c",
"children":[
"Antiretroviral therapy (ART) has extraordinary potential to reduce new infections in addition to benefiting the treated person. Successful treatment is associated with significant reductions in HIV transmission. Although reducing viral load to an undetectable level in blood does not prove absence of virus in semen or vaginal fluid, the rate of transmission from a sexual partner with undetectable blood viral load has been demonstrated to be close to zero, at a level the CDC called “effectively no risk” in a September 2017 statement; hence the slogan “Undetectable = Untransmissible” (“U=U”). Also termed “treatment as prevention” (TasP), maintaining an HIV RNA level less than 200 copies/mL (documented for ≥6 months) with ART prevents HIV transmission to sexual partners. In what is known as the “treatment cascade,” medical care necessary to achieve successful viral suppression consists of testing and diagnosing infected persons, linking them to health care for counseling and treatment, keeping them in a treatment program, and ensuring antiretroviral and other treatment adherence. Each step along this continuum of care is a potential obstacle to successful HIV management on a personal and public health level. Even high-income countries have poor rates of retention in care and adherence to medication. The CDC estimates that the undiagnosed and not-in-care groups with HIV infection were responsible for 80% of HIV transmissions in the United States in 2016."
]
},
{
"type":"p",
"hlId":"20df8c",
"children":[
"Postexposure prophylaxis has been used successfully for many years to prevent infection after occupational and nonoccupational HIV exposure. Prophylaxis should be started as soon as possible after exposure; it is not recommended if more than 72 hours have passed. A three-drug regimen is given for 4 weeks; the preferred regimen is tenofovir disoproxil fumarate (TDF) and emtricitabine plus either raltegravir or dolutegravir (see Management of Pregnant Patients for information on dolutegravir in pregnancy). The exposed person should undergo HIV testing at baseline and at 4 to 6 weeks, 3 months, and 6 months after exposure. ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_a_id_f35",
"wrapId":"2",
"children":[
"Figure 35"
]
}
]
},
" shows an algorithm for evaluation of possible HIV exposure."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_a_id_f35"
]
},
{
"type":"p",
"hlId":"02a7c7",
"children":[
"The U.S. Preventive Services Task Force (USPSTF) and CDC recommend pre-exposure prophylaxis (PrEP) with ART to reduce the risk of infection for persons at high risk of HIV acquisition, including men who have sex with men, persons at risk through heterosexual contact, and persons who inject drugs ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t61",
"wrapId":"3",
"children":[
"Table 61"
]
}
]
},
")"
]
},
". A two-drug combination of TDF and emtricitabine, taken once daily, is FDA approved for HIV PrEP; with proven adherence, it has been shown to be more than 90% effective in reducing infection in those at high risk. Additionally, the FDA recently approved once-daily tenofovir alafenamide (TAF) and emtricitabine for HIV PrEP, excluding in persons who have receptive vaginal intercourse. Patients should also be counseled on the need to continue barrier precautions, on medication toxicity, and on continued risk for other sexually transmitted infections (STIs). Testing should be performed for HIV, hepatitis B virus (HBV), kidney function, and pregnancy before PrEP initiation; monitoring for HIV, other STIs, and pregnancy every 3 months and performing kidney function assessment every 6 months are also recommended during PrEP therapy. Persons taking PrEP who test positive for HIV should have a third drug (either ritonavir-boosted darunavir or dolutegravir) added to the two-drug PrEP regimen pending results of HIV RNA and viral resistance testing. The evidence is conflicting concerning potentially increased high-risk behavior and incidence of other STIs in PrEP users during therapy. PrEP has also been calculated to have favorable cost effectiveness, well below that for other accepted preventive health measures."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_a_id_t61"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"dffff0",
"children":[
"Reducing viral load to an undetectable level in blood reduces the rate of HIV transmission from a sexual partner to close to zero; “Undetectable = Untransmissible” (“U = U”)."
]
},
{
"type":"keypoint",
"hlId":"341336",
"children":[
"Postexposure prophylaxis with a three-drug regimen (tenofovir disoproxil fumarate and emtricitabine plus either raltegravir or dolutegravir) should be started as soon as possible after HIV exposure; it is not recommended if more than 72 hours have passed."
]
},
{
"type":"keypoint",
"hlId":"4ae3d5",
"children":[
"Pre-exposure prophylaxis with two antiretroviral medications (tenofovir disoproxil fumarate or tenofovir alafenamide, plus emtricitabine) is recommended in select persons at high risk for exposure to HIV to reduce the risk of infection."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_2",
"title":{
"__html":"Pathophysiology and Natural History"
},
"titleNode":{
"type":"section-title",
"hlId":"ed23d5",
"children":[
"Pathophysiology and Natural History"
]
},
"children":[
{
"type":"p",
"hlId":"18477f",
"children":[
"Most persons with acute HIV infection are symptomatic; however, because symptoms are nonspecific and self-limited, most acute infections are not diagnosed accurately. The frequency of signs and symptoms at presentation is shown in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t62",
"wrapId":"4",
"children":[
"Table 62"
]
}
]
},
". During symptomatic acute infection, the fourth-generation antibody and p24 antigen testing may not yet be positive, and diagnosis depends on an HIV viral load test demonstrating HIV RNA."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_a_id_t62"
]
},
{
"type":"p",
"hlId":"9300f1",
"children":[
"Patients with chronic HIV infection may present with opportunistic infections, especially when CD4 counts are less than 200/µL, meeting the definition for AIDS (see Opportunistic Infections). Even before progression to AIDS, patients with HIV infection may present with recurrent or severe episodes of infections that do not qualify as opportunistic. Other symptoms can result from chronic HIV infection itself, including lymphadenopathy, fever, night sweats, fatigue, weight loss, chronic diarrhea, and various oral and skin conditions (seborrheic dermatitis, eosinophilic folliculitis, xerosis, atopic dermatitis, and psoriasis). HIV should also be considered in patients with unexplained cytopenias or nephropathy."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"ebd239",
"children":[
"Most persons with acute HIV infection are symptomatic; however, because symptoms are nonspecific and self-limited, most acute infections are not diagnosed accurately."
]
},
{
"type":"keypoint",
"hlId":"9d3e85",
"children":[
"During symptomatic acute infection, the fourth-generation IgM and IgG antibody and p24 antigen may not yet be detectable, and diagnosis depends on an HIV viral load test demonstrating HIV RNA."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_3",
"title":{
"__html":"Screening and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"4b0eb9",
"children":[
"Screening and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"9af2d6",
"children":[
"Testing only symptomatic persons neglects numerous persons who are infected. Thus, the CDC, American College of Physicians, Infectious Diseases Society of America, and USPSTF recommend universal screening for HIV in all adults at least once. The CDC recommends those at higher risk undergo repeat HIV testing at least annually. In 2017, the CDC reaffirmed its support for this recommendation but noted that clinicians can consider the potential benefits of more frequent HIV screening (e.g., every 3 or 6 months) for some asymptomatic sexually active men who have sex with men based on their individual risk factors, local HIV epidemiology, and local policies."
]
},
{
"type":"p",
"hlId":"dd6cdc",
"children":[
"The fourth-generation HIV testing uses a combination assay for HIV antibody and HIV p24 antigen, which detects acute infection 15 to 20 days after the onset of infection. The testing algorithm is outlined in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_a_id_f36",
"wrapId":"5",
"children":[
"Figure 36"
]
}
]
},
". In chronic infection, the initial combination assay is nearly 100% sensitive and specific, but testing in low prevalence populations (such as general screening) can still result in false positives, so waiting for the results of the confirmatory antibody differentiation immunoassay or nucleic acid amplification testing is important for a definitive diagnosis."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_a_id_f36"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"66de07",
"children":[
"It is recommended that all adults be tested for HIV infection at least once."
]
},
{
"type":"keypoint",
"hlId":"771911",
"children":[
"The fourth-generation HIV testing uses a combination assay for HIV antibody and HIV p24 antigen and is nearly 100% sensitive and specific for chronic HIV infection."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_4",
"title":{
"__html":"Initiation of Care"
},
"titleNode":{
"type":"section-title",
"hlId":"fa0a6d",
"children":[
"Initiation of Care"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_id_s18_4_1",
"title":{
"__html":"Initial Evaluation and Laboratory Testing"
},
"titleNode":{
"type":"section-title",
"hlId":"df6f44",
"children":[
"Initial Evaluation and Laboratory Testing"
]
},
"children":[
{
"type":"p",
"hlId":"8f84f9",
"children":[
"All persons who test positive for HIV should immediately be referred to a health care provider with HIV infection management expertise. Initial evaluation should include complete history (including social and sexual) and examination for signs and symptoms of opportunistic infection or other complications. Patient education and counseling should include information on transmission and prevention. Initial laboratory tests include baseline organ function and evaluation for other infections with higher prevalence in persons with HIV ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t63",
"wrapId":"6",
"children":[
"Table 63"
]
}
]
},
")"
]
},
". A baseline CD4 cell count guides opportunistic infection prophylaxis, and a baseline viral load supports monitoring ART effectiveness (see Management of HIV Infection)."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_a_id_t63"
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_4_2",
"title":{
"__html":"Immunizations and Prophylaxis for Opportunistic Infections"
},
"titleNode":{
"type":"section-title",
"hlId":"970e07",
"children":[
"Immunizations and Prophylaxis for Opportunistic Infections"
]
},
"children":[
{
"type":"p",
"hlId":"e87229",
"children":[
"Numerous immunizations are recommended for all persons with HIV, starting with the 20-valent or 15-valent pneumococcal conjugate vaccine (PCV20/PCV15). If the PCV15 is used, it should be followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) at least 8 weeks later. Patients who are not already immune or infected with HBV should receive the hepatitis B vaccine series. Influenza, COVID-19, tetanus-diphtheria-pertussis, hepatitis A, and human papillomavirus vaccinations are indicated as for the general population; however, the live, attenuated influenza vaccine is contraindicated. Measles-mumps-rubella and varicella vaccines can be given as long as the CD4 cell count is greater than 200/µL. The recombinant zoster vaccine should be given to individuals 19 years and older. All persons with HIV infection should be vaccinated for meningococcal disease with the quadrivalent meningococcal vaccine, including boosters every 5 years."
]
},
{
"type":"p",
"hlId":"e82f90",
"children":[
"Prophylaxis for opportunistic infections depends on the patient's CD4 cell count ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t64",
"wrapId":"7",
"children":[
"Table 64"
]
}
]
},
")"
]
},
". Before beginning prophylaxis, active infection should be ruled out clinically and with any indicated testing to avoid undertreatment and selection for resistance, especially for tuberculosis and disseminated ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium avium"
]
},
" complex."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_a_id_t64"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"5c64c6",
"children":[
"All persons with HIV should receive the pneumococcal vaccine(s), hepatitis B vaccine series (in those not already infected or immune), and meningococcal vaccine; the recombinant zoster vaccine should be given to individuals 19 years and older."
]
},
{
"type":"keypoint",
"hlId":"cb22fb",
"children":[
"COVID-19, influenza, tetanus-diphtheria-pertussis, hepatitis A, and human papillomavirus vaccines are indicated as for the general population."
]
},
{
"type":"keypoint",
"hlId":"0d89d3",
"children":[
"Measles-mumps-rubella and varicella vaccines can be given as long as the CD4 cell count is greater than 200/µL."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_5",
"title":{
"__html":"Complications of HIV Infection in the Antiretroviral Therapy Era"
},
"titleNode":{
"type":"section-title",
"hlId":"d3b08a",
"children":[
"Complications of HIV Infection in the Antiretroviral Therapy Era"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_id_s18_5_1",
"title":{
"__html":"Metabolic, Kidney, and Liver Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"1a0e05",
"children":[
"Metabolic, Kidney, and Liver Disorders"
]
},
"children":[
{
"type":"p",
"hlId":"32e323",
"children":[
"As HIV has become a treatable illness and persons with HIV age, metabolic disorders and specific organ diseases have become increasingly significant. HIV infection itself may be associated with manifestations of accelerated aging, and neurocognitive impairment can be exacerbated by HIV. Age-associated comorbidities and declines in kidney and liver function can also complicate management through drug interactions and increased toxicity."
]
},
{
"type":"p",
"hlId":"8680a1",
"children":[
"HIV infection itself and some antiretrovirals affect lipids and can worsen hyperlipidemia; this is especially true for boosted protease inhibitor–based regimens, which can also worsen insulin resistance. Fasting glucose or hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" and lipid levels should be checked at baseline and 3 months after initiating or changing antiretrovirals; hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" should not be used for the diagnosis of diabetes in those taking ART."
]
},
{
"type":"p",
"hlId":"1d7712",
"children":[
"Chronic kidney disease is increasingly common in HIV infection, although, with effective ART, it is less often attributed to HIV nephropathy. It is recommended that kidney function be assessed at least every 6 months in patients with HIV. Tenofovir, a very commonly used nucleoside analogue, is associated with risk for tubular nephrotoxicity, which usually manifests as proteinuria. Patients using a regimen containing tenofovir should undergo urinalysis or quantitative measurement of urine protein twice per year."
]
},
{
"type":"p",
"hlId":"8534a4",
"children":[
"Bone mineral density is reduced in HIV, and tenofovir is also associated with possible worsening of bone density. Dual-energy x-ray absorptiometry scanning is recommended in men older than 50 years, postmenopausal women, patients with a history of fragility fracture, those with chronic glucocorticoid use, and those at high risk for falls. The newer prodrug of tenofovir, TAF, achieves high intracellular levels of active drug with much lower dosing and lower systemic levels compared with the older formulation, TDF. Compared with TDF, TAF has equal antiviral efficacy with reduced kidney and bone toxicity and should be used preferentially over TDF in patients with or at risk for bone or kidney disease."
]
},
{
"type":"p",
"hlId":"c44eb2",
"children":[
"Liver disease is also increased in HIV infection, often because of coinfection with hepatitis B or C virus. All patients with HIV should be screened for hepatitis B and C viruses and immunized if they are HBV negative. If coinfected with HIV and HBV, patients should receive treatment with a TDF or TAF plus emtricitabine or lamivudine–based regimen, which treats both viruses. Patients coinfected with hepatitis C virus should be given a course of curative direct-acting antiviral treatment, although attention must be paid to drug interactions between the antiviral regimens (see ",
{
"type":"cross-reference",
"target":"mk19_a_gi_s6_2_3",
"children":[
"MKSAP 19 Gastroenterology and Hepatology"
]
},
")."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"90d25d",
"children":[
"Fasting glucose or hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" and lipid levels should be checked at baseline and 3 months after initiating or changing antiretroviral therapy; hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" should not be used for the diagnosis of diabetes in those taking antiretroviral therapy."
]
},
{
"type":"keypoint",
"hlId":"3fb47f",
"children":[
"Tenofovir disoproxil fumarate (TDF) is associated with increased risks of tubular nephrotoxicity and worsening of bone mineral density; tenofovir alafenamide should be used preferentially over TDF in patients with or at risk for bone or kidney disease."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_5_2",
"title":{
"__html":"Cardiovascular Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"6ef655",
"children":[
"Cardiovascular Disease"
]
},
"children":[
{
"type":"p",
"hlId":"1a4679",
"children":[
"Rates of cardiovascular disease, including myocardial infarction and stroke, are higher in persons with HIV infection; this association remains after correction for increased risk factors such as smoking. Some of the increase may result from hyperlipidemia, but evidence indicates that the increase partially results from HIV infection being a chronic inflammatory state. It is clear that patients with untreated HIV infection have a higher risk of cardiovascular events compared with patients taking effective ART, regardless of any worsening of lipid levels from the ART. Attention to traditional risk factors such as smoking, lipid levels, and hypertension is crucial in patients with HIV, as is use of statin therapy (with attention to drug interactions between some statins and some antiretrovirals) based on current risk calculations. Guidelines from the American College of Cardiology/American Heart Association recommend patients with HIV infection and borderline risk for atherosclerotic cardiovascular disease (5% to <7.5%) should be engaged in risk discussion regarding initiating moderate-intensity statin therapy. An international multicenter trial is addressing whether patients with HIV should be treated with statins even with a 10-year risk less than 7.5%."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"675ff9",
"children":[
"Rates of cardiovascular disease, including myocardial infarction and stroke, are higher in persons with HIV infection; control of cardiovascular risk factors (smoking, lipid levels, and hypertension) is essential, including statin therapy based on clinical risk calculations."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_5_3",
"title":{
"__html":"Neurocognitive Decline"
},
"titleNode":{
"type":"section-title",
"hlId":"b11f0f",
"children":[
"Neurocognitive Decline"
]
},
"children":[
{
"type":"p",
"hlId":"957af5",
"children":[
"Screening for neurologic complications, especially cognitive impairment, is important at entry into HIV care. Assessment should be repeated in older adults, especially if concerns arise regarding adherence to care and ART. As persons living with HIV age, neurocognitive impairment may be exacerbated by the effect of HIV infection on the brain. Classified as HIV-associated neurocognitive disorders (HAND), manifestations range from asymptomatic neurocognitive impairment to severe HIV-associated dementia (HAD). ART initiation and continuation is the main treatment for HAND, and it has a clear role in prevention and treatment of HAD."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"ca4842",
"children":[
"Manifestations of HIV-associated neurocognitive disorders (HAND) range from asymptomatic neurocognitive impairment to severe HIV-associated dementia; if not already being provided, ART should be instituted immediately as part of prevention and treatment of HAND."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_5_4",
"title":{
"__html":"Immune Reconstitution Inflammatory Syndrome"
},
"titleNode":{
"type":"section-title",
"hlId":"5503bd",
"children":[
"Immune Reconstitution Inflammatory Syndrome"
]
},
"children":[
{
"type":"p",
"hlId":"01804f",
"children":[
"Immune reconstitution inflammatory syndrome (IRIS) is a disorder associated with worsening of a pre-existing infectious process (paradoxical IRIS) or with revelation of a previously unrecognized pre-existing infection (unmasking IRIS). It has also been reported with noninfectious complications, such as lymphoma. IRIS usually occurs within a few months of initiating effective ART in patients with low pretreatment CD4 cell counts (<100/µL). Management includes continuing ART while treating the opportunistic infection. In select patients, NSAIDs or glucocorticoids may be useful in mitigating inflammatory symptoms."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"9cf62c",
"children":[
"Immune reconstitution inflammatory syndrome is caused by an inflammatory response to a pre-existing infectious process; it usually occurs within a few months of initiating effective antiretroviral therapy and presents with a wide variety of infections and noninfectious complications."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_5_5",
"title":{
"__html":"Opportunistic Infections"
},
"titleNode":{
"type":"section-title",
"hlId":"4c80b7",
"children":[
"Opportunistic Infections"
]
},
"children":[
{
"type":"p",
"hlId":"acf45d",
"children":[
"Mucocutaneous ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
" infections can occur in HIV-infected patients at relatively preserved CD4 cell counts. HIV-infected patients do not usually develop invasive ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
" infection unless they have other risk factors. Oral candidiasis usually presents as thrush, with mucosal whitish plaques ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_a_id_f37",
"wrapId":"8",
"children":[
"Figure 37"
]
}
]
},
")"
]
},
", and can be treated topically (e.g., with clotrimazole troches) or with a short course of oral fluconazole. Swallowing symptoms suggest esophageal disease, which requires systemic treatment, such as fluconazole, for a longer course; a lack of treatment response is an indication for endoscopy."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_a_id_f37"
]
},
{
"type":"p",
"hlId":"80a879",
"children":[
"Reactivation of latent tuberculosis is also significantly increased in HIV infection, even without a decreased CD4 cell count. Tuberculosis is also more likely to present in extrapulmonary sites or with an atypical chest radiograph. Tuberculosis treatment in HIV must consider interactions of rifamycins with many antiretrovirals."
]
},
{
"type":"p",
"hlId":"6d9565",
"children":[
"Infections with other opportunistic organisms usually occur at CD4 cell counts less than 200/µL. ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pneumocystis jirovecii"
]
},
" pneumonia usually presents as a subacute illness with fever, dyspnea, and dry cough in a patient with a CD4 cell count less than 200/µL who is not receiving prophylaxis. Chest radiographs most often show bilateral interstitial infiltrates; cavitation or pleural effusion is unusual and suggests another diagnosis. A normal chest radiograph does not exclude the diagnosis, and chest CT is more sensitive, demonstrating patchy “ground-glass” opacities. Normal lactate dehydrogenase levels and stable exercise oxygen saturation have a high negative predictive value, but elevated lactate dehydrogenase levels and oxygen desaturation with exercise are nonspecific. Diagnosis depends on demonstration of causative organisms and often requires bronchoscopy. The treatment of choice is high-dose trimethoprim-sulfamethoxazole; patients with hypoxia at presentation should be given adjunctive glucocorticoids to prevent worsening that may accompany treatment initiation."
]
},
{
"type":"p",
"hlId":"90d75e",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Cryptococcus"
]
},
" infection usually presents as subacute meningitis with headache, mental status changes, and fever. The diagnosis can be made most swiftly by antigen testing of cerebrospinal fluid and blood. Management includes antifungal therapy and attention to increased intracranial pressure, which is usually responsible for the morbidity and mortality associated with cryptococcal meningitis (see ",
{
"type":"cross-reference",
"target":"mk19_a_id_s8_3",
"children":[
"Fungal Infections"
]
},
")."
]
},
{
"type":"p",
"hlId":"5e930f",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Toxoplasma gondii"
]
},
" infection in AIDS usually presents in patients with CD4 cell counts less than 100/µL. Because it is a reactivation disease, patients are usually serology positive. Clinical presentation includes headache, fever, and focal neurologic deficits. Imaging by CT or MRI (which is more sensitive) reveals multiple ring-enhancing lesions ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_a_id_f38",
"wrapId":"9",
"children":[
"Figure 38"
]
}
]
},
")"
]
},
". The differential diagnosis includes primary central nervous system (CNS) lymphoma, which most often appears as a single lesion on imaging, and progressive multifocal leukoencephalopathy, which is usually nonenhancing. Diagnosis of CNS toxoplasmosis is usually presumptive based on presentation, imaging, and response to empiric treatment."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_a_id_f38"
]
},
{
"type":"p",
"hlId":"42f178",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium avium"
]
},
" complex infection usually presents as disseminated disease in patients with CD4 cell counts less than 50/µL; symptoms and signs include fever, sweats, weight loss, hepatosplenomegaly, lymphadenopathy, and cytopenias. Blood cultures for acid-fast bacilli will usually grow ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"M. avium"
]
},
" complex, but it may also be found on lymph node or liver biopsy when necessary."
]
},
{
"type":"p",
"hlId":"107990",
"children":[
"Cytomegalovirus most commonly presents with CD4 cell counts less than 50/µL. Cytomegalovirus retinitis, presenting with vision changes or floaters, is much more likely in AIDS than in other immunocompromised conditions, such as after transplantation. Gastrointestinal cytomegalovirus disease is also common, most often as esophagitis or colitis."
]
},
{
"type":"p",
"hlId":"0988fa",
"children":[
"Patients with AIDS are also more likely to develop certain malignancies, especially those related to viruses. Non-Hodgkin lymphoma, especially primary CNS lymphoma related to Epstein-Barr virus, is significantly increased compared with age-matched controls. Kaposi sarcoma is caused by human herpes virus type 8 and presents as dark red, brown, or violaceous lesions of the skin or mucous membranes ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_a_id_f39",
"wrapId":"10",
"children":[
"Figure 39"
]
}
]
},
")"
]
},
"; human herpes virus type 8 can also cause primary effusion lymphoma and Castleman disease (giant lymph node hyperplasia). Human papillomavirus–related malignancies are significantly increased in HIV, including cervical and anal cancers, and regular guideline-based screening is important."
]
},
{
"type":"inline-wrap",
"wrapId":"10",
"contentIds":[
"mk19_a_id_f39"
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_5_6",
"title":{
"__html":"Hematologic Disorders"
},
"titleNode":{
"type":"section-title",
"hlId":"74aa40",
"children":[
"Hematologic Disorders"
]
},
"children":[
{
"type":"p",
"hlId":"89babd",
"children":[
"HIV infection can be associated with hematologic abnormalities, including lymphopenia, neutropenia, anemia, and thrombocytopenia. Reasons for these cytopenias include HIV infection itself (defective hematopoiesis and bone marrow suppression), secondary infections, associated malignancies, and immune-related conditions (e.g., immune thrombocytopenic purpura, thrombotic thrombocytopenic purpura, hemophagocytic lymphohistiocytosis). Modern antiretroviral medications are unlikely to cause cytopenias. Those who are acutely ill with a low CD4 cell count (<200/µL) should be expeditiously and extensively evaluated for these causes. Bone marrow evaluation may be required in some cases. Empiric treatment for infection or microangiopathies may be needed, and ART and treatment of the underlying cause is essential. In stable patients with a hematologic abnormality as the presenting sign of HIV illness, ART often reverses the cytopenia."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"f3a855",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pneumocystis jirovecii"
]
},
" pneumonia usually presents as a subacute illness with fever, dyspnea, and dry cough; although chest radiographs most often show bilateral interstitial infiltrates, a normal chest radiograph does not exclude the diagnosis."
]
},
{
"type":"keypoint",
"hlId":"1eac72",
"children":[
"Successful management of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Cryptococcus"
]
},
" infection in patients with HIV includes antifungal therapy and attention to increased intracranial pressure, which is usually responsible for the morbidity and mortality associated with cryptococcal meningitis."
]
},
{
"type":"keypoint",
"hlId":"4a8135",
"hvc":true,
"children":[
"MRI is more sensitive than CT in revealing the characteristic ring-enhancing lesions of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Toxoplasma gondii"
]
},
" infection in patients with HIV."
]
},
{
"type":"keypoint",
"hlId":"3210b9",
"children":[
"In patients with a hematologic abnormality as the initial sign of HIV infection, antiretroviral therapy often reverses the cytopenia."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_6",
"title":{
"__html":"Management of HIV Infection"
},
"titleNode":{
"type":"section-title",
"hlId":"396251",
"children":[
"Management of HIV Infection"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_id_s18_6_1",
"title":{
"__html":"When to Initiate Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"2d2ead",
"children":[
"When to Initiate Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"921870",
"children":[
"All persons with HIV infection should begin ART as soon as they are ready, regardless of CD4 cell count. Rapid initiation of ART (on the day or within 2 weeks of initial diagnosis) has been shown to improve viral suppression and should be considered if no medical (symptoms suggesting opportunistic infections in which immediate ART is contraindicated) or structural (staffing and linkage to care service availability) barriers prevent doing so."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_6_2",
"title":{
"__html":"Antiretroviral Regimens"
},
"titleNode":{
"type":"section-title",
"hlId":"aea4c3",
"children":[
"Antiretroviral Regimens"
]
},
"children":[
{
"type":"p",
"hlId":"114134",
"children":[
"Antiretroviral agents used in the United States are shown in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t65",
"wrapId":"11",
"children":[
"Table 65"
]
}
]
},
". Standards for effective antiretroviral regimens include use of three drugs from two different classes, preferably combining two nucleoside reverse transcriptase inhibitors with an integrase strand transfer inhibitor. Preferred regimens also feature a high barrier to resistance, good tolerability and safety, and combination pills with once-daily dosing to facilitate adherence ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t66",
"wrapId":"11",
"children":[
"Table 66"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"11",
"contentIds":[
"mk19_a_id_t65",
"mk19_a_id_t66"
]
},
{
"type":"p",
"hlId":"6b9bee",
"children":[
"Patients with or at risk for reduced kidney function or osteopenia should not be given TDF. To reduce the risk of hypersensitivity, patients who are prescribed abacavir must first undergo HLA-B*57:01 testing to show they are negative. Many antiretrovirals interact with other drugs, and potential drug interactions must always be assessed when beginning HIV therapy or beginning any drug for someone already taking ART. Such assessment is especially necessary when pharmacokinetic boosters (ritonavir or cobicistat) are used specifically to inhibit drug metabolism and raise levels of antiretrovirals."
]
},
{
"type":"p",
"hlId":"9216f4",
"children":[
"Viral load levels and CD4 cell counts are monitored to ensure effectiveness and to determine immune recovery. With optimal therapy, HIV RNA in blood should become and stay undetectable. CD4 cell counts will increase, although cell counts may take time to improve and may not show full recovery, especially in those who are older or who have other factors affecting lymphocytes. Patients taking ART who are stable with a CD4 cell count of 500/µL or more for more than 2 years can stop T-cell monitoring as long as viral load remains undetectable."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_6_3",
"title":{
"__html":"Resistance Testing"
},
"titleNode":{
"type":"section-title",
"hlId":"d1e86e",
"children":[
"Resistance Testing"
]
},
"children":[
{
"type":"p",
"hlId":"71580e",
"children":[
"Viral resistance testing should be performed at baseline to ensure selection of a fully active regimen and should be repeated if the viral load increases during ART. The most common reason for breakthrough viremia is poor medication adherence. Plasma levels of HIV RNA must generally be greater than 500 copies/mL to provide enough virus for resistance testing. Viral resistance testing can be genotypic (looking for mutations associated with drug resistance) or phenotypic (assessing whether virus can replicate in the presence of the drug). Genotypic testing is faster, cheaper, and more commonly used. Resistance testing results are used to guide selection of a new regimen in the event resistant virus develops, but previous resistance testing results as well as previous regimens and responses must also be considered. Resistance testing may not be reliable if performed while the patient is not taking an antiretroviral regimen because resistance may not be detectable without the selective pressure of the antiretrovirals. Once selected for, previous mutations are generally archived in the viral population and may re-emerge even if resistance testing does not demonstrate the mutation. A regimen may also be switched because of adverse effects or to ease adherence or avoid drug interactions. Laboratory monitoring tests should be repeated 1 month after switching regimens to assess effectiveness and toxicity."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"2ab07c",
"children":[
"All persons with HIV infection should begin antiretroviral therapy as soon as they are ready, regardless of CD4 cell count."
]
},
{
"type":"keypoint",
"hlId":"a045bb",
"children":[
"Standards for effective antiretroviral regimens include use of three drugs from two different classes; preferred regimens combine two nucleoside reverse transcriptase inhibitors with an integrase strand transfer inhibitor."
]
},
{
"type":"keypoint",
"hlId":"082da5",
"children":[
"Viral resistance testing should be performed at baseline to ensure selection of a fully active regimen and should be repeated if the viral load increases during antiretroviral therapy."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_7",
"title":{
"__html":"Management of Pregnant Patients with HIV Infection"
},
"titleNode":{
"type":"section-title",
"hlId":"fa7ce2",
"children":[
"Management of Pregnant Patients with HIV Infection"
]
},
"children":[
{
"type":"p",
"hlId":"9bd747",
"children":[
"The management of pregnant women with HIV is similar to the management of nonpregnant women. Initiating ART is recommended as soon as possible in pregnant women with HIV who are not already being treated, and it is especially important that women already receiving HIV treatment who become pregnant continue treatment without interruption. ART in pregnancy benefits the woman and significantly reduces the risk of perinatal transmission of HIV to her baby. Recent data show no difference in birth defect rates with some antiretrovirals compared with the general population, including neural tube defects with efavirenz. Initial treatment regimen selection in pregnant women is similar to that for nonpregnant women; however, some antivirals are not recommended (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t65",
"wrapId":"12",
"children":[
"Table 65"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"12",
"contentIds":[
"mk19_a_id_t65"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"5dcadb",
"children":[
"Pregnant women should promptly initiate or continue receiving HIV treatment without interruption; efavirenz and tenofovir disoproxil fumarate can be safely used."
]
},
{
"type":"keypoint",
"hlId":"2596ab",
"children":[
"In pregnant women with HIV, bictegravir and tenofovir alafenamide are not recommended."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s18_8",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016. Updated May 23, 2018. Available at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://stacks.cdc.gov/view/cdc/38856",
"target":"_blank"
},
"children":[
"https://stacks.cdc.gov/view/cdc/38856"
]
},
"."
]
},
{
"type":"reference",
"children":[
"Centers for Disease Control and Prevention (CDC), US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update: A clinical practice guideline. CDC website. Available at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf",
"target":"_blank"
},
"children":[
"https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf"
]
},
"."
]
},
{
"type":"reference",
"children":[
"Li Z, Purcell DW, Sansom SL, et al. Vital signs: HIV transmission along the continuum of care - United States, 2016. MMWR Morb Mortal Wkly Rep. 2019;68:267-272. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30897075",
"target":"_blank"
},
"children":[
"PMID: 30897075"
]
},
" doi:10.15585/mmwr.mm6811e1"
]
},
{
"type":"reference",
"children":[
"Murthy N, Wodi AP, Bernstein H, et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:229-233. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/35176010",
"target":"_blank"
},
"children":[
"PMID: 35176010"
]
},
" doi:10.15585/mmwr.mm7107a1"
]
},
{
"type":"reference",
"children":[
"Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement. JAMA. 2019;321:2203-2213. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31184747",
"target":"_blank"
},
"children":[
"PMID: 31184747"
]
},
" doi:10.1001/jama.2019.6390"
]
},
{
"type":"reference",
"children":[
"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2019. Available at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0",
"target":"_blank"
},
"children":[
"https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0"
]
}
]
},
{
"type":"reference",
"children":[
"Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Updated July 16, 2019. Available at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/0",
"target":"_blank"
},
"children":[
"https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/0"
]
}
]
},
{
"type":"reference",
"children":[
"Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Updated March 27, 2018. Available at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://aidsinfo.nih.gov/guidelines/html/3/perinatal/0",
"target":"_blank"
},
"children":[
"https://aidsinfo.nih.gov/guidelines/html/3/perinatal/0"
]
}
]
},
{
"type":"reference",
"children":[
"Thompson MA, Horberg MA, Agwu AL, et al. Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2020 Nov 6:ciaa1391. Epub ahead of print. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33225349",
"target":"_blank"
},
"children":[
"PMID: 33225349"
]
},
" doi:10.1093/cid/ciaa1391"
]
},
{
"type":"reference",
"children":[
"Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. N Engl J Med. 2018;378:1029-1041. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29539283",
"target":"_blank"
},
"children":[
"PMID: 29539283"
]
},
" doi:10.1056/NEJMra1615896"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_a_id_t60":{
"id":"mk19_a_id_t60",
"number":60,
"bookId":"id",
"title":{
"__html":"Risk of HIV-1 Transmission per Single Exposure"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"9d29f2",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 60. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t60"
}
]
},
"Risk of HIV-1 Transmission per Single Exposure"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"df10da",
"class":"col hd l",
"children":[
"Exposure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6daba3",
"class":"col hd l",
"children":[
"Risk (%)"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3cf2df",
"class":"cell txt l",
"children":[
"Occupational—needlestick"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f11bf",
"class":"cell txt l",
"children":[
"0.23"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2346e4",
"class":"cell txt l",
"children":[
"Occupational—mucous membrane"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"305cf1",
"class":"cell txt l",
"children":[
"0.09"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"013913",
"class":"cell txt l",
"children":[
"Needle-sharing injection drug use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b9c48c",
"class":"cell txt l",
"children":[
"0.63"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ba6f23",
"class":"cell txt l",
"children":[
"Receptive anal intercourse"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e605c",
"class":"cell txt l",
"children":[
"1.4"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a458f9",
"class":"cell txt l",
"children":[
"Receptive vaginal intercourse"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37d5c0",
"class":"cell txt l",
"children":[
"0.08"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2b35b8",
"class":"cell txt l",
"children":[
"Insertive anal intercourse"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"27e795",
"class":"cell txt l",
"children":[
"0.11"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6477a0",
"class":"cell txt l",
"children":[
"Insertive vaginal intercourse"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e38502",
"class":"cell txt l",
"children":[
"0.04"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"54ed91",
"class":"cell txt l",
"children":[
"Oral sex"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"04817e",
"class":"cell txt l",
"children":[
"0.01"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_a_id_t61":{
"id":"mk19_a_id_t61",
"number":61,
"bookId":"id",
"title":{
"__html":"Persons at High Risk of HIV Acquisition Who Should be Considered for PrEP<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"3588c9",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 61. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t61"
}
]
},
"Persons at High Risk of HIV Acquisition Who Should be Considered for PrEP",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"855697",
"class":"col hd l",
"children":[
"Men Who Have Sex with Men"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0cc59b",
"class":"col hd l",
"children":[
"Heterosexual Men & Women"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d2e562",
"class":"col hd l",
"children":[
"Persons Who Use Injection Drugs"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0d6c8",
"class":"cell txt l",
"children":[
"Serodiscordant sexual partner"
]
},
" ",
{
"type":"p",
"hlId":"84aee9",
"class":"cell txt l",
"children":[
"Inconsistent condom use during insertive or receptive anal sex"
]
},
" ",
{
"type":"p",
"hlId":"d755e4",
"class":"cell txt l",
"children":[
"STI with chlamydia, gonorrhea, or syphilis within the previous 6 months"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0d6c8",
"class":"cell txt l",
"children":[
"Serodiscordant sexual partner"
]
},
" ",
{
"type":"p",
"hlId":"03b64d",
"class":"cell txt l",
"children":[
"Inconsistent condom use with a partner whose HIV status is unknown or who is at high risk themselves"
]
},
" ",
{
"type":"p",
"hlId":"b83f9c",
"class":"cell txt l",
"children":[
"STI with syphilis or gonorrhea within the previous 6 months"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eaf9a8",
"class":"cell txt l",
"children":[
"Shared use of drug injection equipment"
]
},
" ",
{
"type":"p",
"hlId":"0b7c38",
"class":"cell txt l",
"children":[
"At risk of sexual acquisition of HIV as described for other risk groups"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"PrEP = pre-exposure prophylaxis; STI = sexually transmitted infection."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Each group is considered at high risk of HIV acquisition if they possess at least one of the listed characteristics. Additionally, persons who engage in transactional sex, persons who are trafficked for sex work, men who have sex with men and women, and transgender women and men who are sexually active can be at high risk of HIV infection and should be considered for PrEP based on the criteria outlined above. Transgender women are at especially high risk."
]
]
},
"mk19_a_id_t62":{
"id":"mk19_a_id_t62",
"number":62,
"bookId":"id",
"title":{
"__html":"Signs and Symptoms of Acute HIV Infection (Acute Retroviral Syndrome)"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"7a2bab",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 62. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t62"
}
]
},
"Signs and Symptoms of Acute HIV Infection (Acute Retroviral Syndrome)"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0dde0e",
"class":"col hd l",
"children":[
"Sign/Symptom"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"791c3b",
"class":"col hd l",
"children":[
"Frequency (%)"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5780df",
"class":"cell txt l",
"children":[
"Fever"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d09bf4",
"class":"cell txt l",
"children":[
"75"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b5ff1b",
"class":"cell txt l",
"children":[
"Fatigue"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a3f390",
"class":"cell txt l",
"children":[
"68"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"46dc35",
"class":"cell txt l",
"children":[
"Myalgia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f457c5",
"class":"cell txt l",
"children":[
"49"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e6ce50",
"class":"cell txt l",
"children":[
"Rash"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"642e92",
"class":"cell txt l",
"children":[
"48"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f5234f",
"class":"cell txt l",
"children":[
"Headache"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6c8349",
"class":"cell txt l",
"children":[
"45"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b33bb7",
"class":"cell txt l",
"children":[
"Pharyngitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d64592",
"class":"cell txt l",
"children":[
"40"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2f8036",
"class":"cell txt l",
"children":[
"Lymphadenopathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d67d8a",
"class":"cell txt l",
"children":[
"39"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b0bd5d",
"class":"cell txt l",
"children":[
"Arthralgia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34173c",
"class":"cell txt l",
"children":[
"30"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e0b64f",
"class":"cell txt l",
"children":[
"Night sweats"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"33e75f",
"class":"cell txt l",
"children":[
"28"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2b9937",
"class":"cell txt l",
"children":[
"Diarrhea"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"02e74f",
"class":"cell txt l",
"children":[
"27"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_a_id_t63":{
"id":"mk19_a_id_t63",
"number":63,
"bookId":"id",
"title":{
"__html":"Recommended Initial Laboratory Screening and Other Studies in Persons with HIV Infection"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"89230a",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 63. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t63"
}
]
},
"Recommended Initial Laboratory Screening and Other Studies in Persons with HIV Infection"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0cbc66",
"class":"col hd l",
"children":[
"Test"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"80f6e5",
"class":"col hd l",
"children":[
"HIV-specific tests for all persons with HIV"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d99e1a",
"class":"cell txt l",
"children":[
"HIV antigen/antibody testing"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"945e4c",
"class":"cell txt l",
"children":[
"If written evidence of diagnosis not available or if viral load low or undetectable"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f969e",
"class":"cell txt l",
"children":[
"CD4 cell count and percentage"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5551f3",
"class":"cell txt l",
"children":[
"Assess need for opportunistic infection prophylaxis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a5376b",
"class":"cell txt l",
"children":[
"Plasma HIV RNA polymerase chain reaction (HIV viral load)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6d8a48",
"class":"cell txt l",
"children":[
"Establish baseline and monitor viral suppression"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ddb4c",
"class":"cell txt l",
"children":[
"HIV resistance testing"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10db03",
"class":"cell txt l",
"children":[
"Baseline genotype for protease inhibitor, nonnucleoside RTI, nucleoside/nucleotide RTI mutations for persons who have never initiated therapy, are reengaging in care and not receiving therapy, or with inconsistent access to therapy. INSTI genotype is recommended only if suspicion for INSTI mutation transmission."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"c6244f",
"class":"col hd l",
"children":[
"Other laboratory tests"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"00274a",
"class":"cell txt l",
"children":[
"Complete blood count with differential"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"decf91",
"class":"cell txt l",
"children":[
"Assess for anemia, neutropenia, thrombocytopenia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"67e7f9",
"class":"cell txt l",
"children":[
"Alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e83a9b",
"class":"cell txt l",
"children":[
"Assess for evidence of liver damage, hepatitis, or systemic infection (e.g., elevated alkaline phosphatase level with some opportunistic infections)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"af1001",
"class":"cell txt l",
"children":[
"Total protein and albumin levels"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6e6901",
"class":"cell txt l",
"children":[
"High total protein level common with untreated HIV infection because of increased immunoglobulin fraction secondary to B-cell hyperplasia; low albumin level may indicate nutritional deficiency or nephrotic syndrome"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f69633",
"class":"cell txt l",
"children":[
"Electrolytes, blood urea nitrogen, creatinine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2fd9db",
"class":"cell txt l",
"children":[
"Assess kidney function; creatinine level for calculation of estimated glomerular filtration rate"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e1ef9b",
"class":"cell txt l",
"children":[
"Lipid profile and blood glucose; hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a52e24",
"class":"cell txt l",
"children":[
"Fasting not needed for initial lipid and glucose assessment; if abnormal, repeat fasting"
]
},
" ",
{
"type":"p",
"hlId":"4e875c",
"class":"cell txt l",
"children":[
"Hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" measured before ART initiation but not used for diagnosis of diabetes in those taking ART"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"747c2a",
"class":"cell txt l",
"children":[
"Urinalysis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1519ff",
"class":"cell txt l",
"children":[
"Assess for evidence of proteinuria, hematuria"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d592c",
"class":"col hd l",
"children":[
"Screening for coinfections"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"309e5c",
"class":"cell txt l",
"children":[
"Cervical Pap test"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e79d16",
"class":"cell txt l",
"children":[
"21-29 years of age: annual Pap test; if three consecutive Pap tests are normal, follow-up screening in 3 years."
]
},
" ",
{
"type":"p",
"hlId":"0678d7",
"class":"cell txt l",
"children":[
"≥30 years of age: three consecutive normal Pap tests without an HPV test, follow-up Pap in 3 years; Pap with HPV testing are both negative, follow-up Pap in 3 years after combined test"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ca2f57",
"class":"cell txt l",
"children":[
"Anal Pap test",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f0268",
"class":"cell txt l",
"children":[
"Anal Pap test for all persons with a history of receptive anal intercourse, genital warts, or abnormal cervical Pap result if access to appropriate referral for follow-up, including high-resolution anoscopy, is available"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"63bc9a",
"class":"cell txt l",
"children":[
"Gonorrhea, chlamydia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8ae870",
"class":"cell txt l",
"children":[
"At least annual screening using nucleic acid amplification testing with sites based on exposure history (e.g., urine, vaginal, rectal, oropharyngeal; three-site testing preferred for all patients)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"44f3ef",
"class":"cell txt l",
"children":[
"Trichomoniasis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8e3a93",
"class":"cell txt l",
"children":[
"Annual screening in all persons who have vaginal sex"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd36aa",
"class":"cell txt l",
"children":[
"Syphilis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b0f648",
"class":"cell txt l",
"children":[
"At least annual screening using local protocol (either rapid plasma reagin or treponemal-specific antibody tests)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7a38d5",
"class":"cell txt l",
"children":[
"Latent ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium tuberculosis"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1a74e6",
"class":"cell txt l",
"children":[
"TST or IGRA; IGRA preferred if history of BCG vaccination"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"498a7f",
"class":"cell txt l",
"children":[
"Varicella-zoster virus"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"69aaf9",
"class":"cell txt l",
"children":[
"Anti-varicella IgG if no known history of chicken pox or shingles"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26c139",
"class":"cell txt l",
"children":[
"Hepatitis A, B, and C virus"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9bcca",
"class":"cell txt l",
"children":[
"HBsAg, HBsAb, HBcAb, HCVAb; HAV total or IgG antibody. If HBsAg+ or HBcAb+, order HBV DNA level; if HCVAb+, order HCV RNA level and HCV genotype. Screen for hepatocellular carcinoma for all adult patients with cirrhosis and noncirrhotic patients with chronic HBV for an extended period."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"17c5e2",
"class":"cell txt l",
"children":[
"Measles titer"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"70d265",
"class":"cell txt l",
"children":[
"Adequate evidence of immunity includes being born in the United States before 1957, written documentation of adequate vaccination, or serologic evidence of immunity. Persons born in the 1960s may have been vaccinated with a vaccine other than MMR and may have waning immunity. Patients may opt to receive a booster MMR vaccine rather than check serology."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ART = antiretroviral therapy; BCG = bacillus Calmette–Guérin; HAV = hepatitis A virus; HBcAb = hepatitis B core antibody; HBsAb = hepatitis B surface antibody; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; HCV = hepatitis C virus; HCVAb = hepatitis C antibody; HPV = human papillomavirus; IGRA = interferon-γ release assay; INSTI = integrase strand transfer inhibitor; MMR = measles, mumps, rubella; RTI = reverse transcriptase inhibitor; TST = tuberculin skin test."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"At this time, no national guidelines are available for this intervention."
],
[
"Adapted with permission from Thompson MA, Horberg MA, Agwu AL, et al. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2020 Nov 6:ciaa1391. Epub ahead of print. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33225349",
"target":"_blank"
},
"children":[
"PMID: 33225349"
]
},
" doi: 10.1093/cid/ciaa1391"
]
]
},
"mk19_a_id_t64":{
"id":"mk19_a_id_t64",
"number":64,
"bookId":"id",
"title":{
"__html":"Prophylaxis against Opportunistic Infections in HIV/AIDS"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"022e4e",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 64. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t64"
}
]
},
"Prophylaxis against Opportunistic Infections in HIV/AIDS"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6988a3",
"class":"col hd l",
"children":[
"Opportunistic Infection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b1583",
"class":"col hd l",
"children":[
"Indication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"92335c",
"class":"col hd l",
"children":[
"Preferred Drug"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0f1a56",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pneumocystis jirovecii"
]
},
" "
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"25b570",
"class":"cell txt l",
"children":[
"CD4 cell count <200/µL",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9f1664",
"class":"cell txt l",
"children":[
"TMP-SMX, double-strength or single-strength tablet once daily",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e82db4",
"class":"cell txt l",
"children":[
"Toxoplasmosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64449b",
"class":"cell txt l",
"children":[
"CD4 cell count <100/µL and positive serologic results",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6201a3",
"class":"cell txt l",
"children":[
"TMP-SMX, double-strength tablet once daily",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ad7577",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium avium"
]
},
" complex"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e3a376",
"class":"cell txt l",
"children":[
"CD4 cell count <50/µL",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9016b8",
"class":"cell txt l",
"children":[
"Azithromycin, 1200 mg once weekly or 600 mg twice weekly; clarithromycin, 500 mg twice daily"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"efb001",
"class":"cell txt l",
"children":[
"Latent tuberculosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c01346",
"class":"cell txt l",
"children":[
"TST >5 mm or positive IGRA results"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9b7058",
"class":"cell txt l",
"children":[
"3 months of isoniazid plus rifapentine given once weekly"
]
},
" ",
{
"type":"p",
"hlId":"3619db",
"class":"cell txt l",
"children":[
"3 months of isoniazid plus rifampin given daily",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
}
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"IGRA = interferon-γ release assay; TMP-SMX = trimethoprim-sulfamethoxazole; TST = tuberculin skin test."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Prophylaxis may be discontinued in patients with CD4 cell count ≥200/µL for ≥3 months; emerging evidence suggests prophylaxis may be discontinued in patients with CD4 cell count of 100-200/µL and a suppressed viral load for ≥3 months."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Alternatives for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pneumocystis jirovecii"
]
},
" prophylaxis may be found here: ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/321/pneumocystis-pneumonia",
"target":"_blank"
},
"children":[
"https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/321/pneumocystis-pneumonia"
]
}
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Alternatives for toxoplasmosis prophylaxis may be found here: ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/322/toxoplasma-gondii",
"target":"_blank"
},
"children":[
"https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/322/toxoplasma-gondii"
]
}
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Prophylaxis no longer recommended in patients who start antiretroviral therapy immediately."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
},
"Drug interactions with first-line antiretroviral therapy regimens (including tenofovir alafenamide, integrase inhibitors) are common, and HIV or latent tuberculosis regimens may need to be modified. Daily pyridoxine is recommended in patients who will receive isoniazid because of the risk for peripheral neuropathy. See ",
{
"type":"cross-reference",
"target":"mk19_a_id_s6_5_1",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycobacterium tuberculosis"
]
},
" Infection"
]
},
" for dosing information. Other organizations may include additional recommended regimens. Recommendations from Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69:1-11. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32053584",
"target":"_blank"
},
"children":[
"PMID: 32053584"
]
},
" doi:10.15585/mmwr.rr6901a1"
]
]
},
"mk19_a_id_t65":{
"id":"mk19_a_id_t65",
"number":65,
"bookId":"id",
"title":{
"__html":"Antiretroviral Agents Used in the United States to Treat HIV Infection"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"ecea74",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 65. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t65"
}
]
},
"Antiretroviral Agents Used in the United States to Treat HIV Infection"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9bd813",
"class":"col hd l",
"children":[
"Class"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1bee0",
"class":"col hd l",
"children":[
"Agent",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8bc11",
"class":"col hd l",
"children":[
"Adverse Effects"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe1d91",
"class":"cell txt l",
"children":[
"Nucleoside RTIs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5081e1",
"class":"cell txt l",
"children":[
"Abacavir"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c156c7",
"class":"cell txt l",
"children":[
"Hypersensitivity",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
" (exclude HLA-B*57:01 before prescribing)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bcab48",
"class":"cell txt l",
"children":[
"Emtricitabine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6b549b",
"class":"cell txt l",
"children":[
"Minimal toxicity; has activity against HBV, and exacerbations have occurred with discontinuation of therapy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5ed6d9",
"class":"cell txt l",
"children":[
"Lamivudine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"63090c",
"class":"cell txt l",
"children":[
"Minimal toxicity; has HBV activity, but dosing differs for HIV and HBV treatment"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ebcaf2",
"class":"cell txt l",
"children":[
"TDF"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"364500",
"class":"cell txt l",
"children":[
"Nausea, kidney disease, Fanconi syndrome, decreased bone density; has activity against HBV, and exacerbations have occurred with discontinuation of therapy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6efe5c",
"class":"cell txt l",
"children":[
"TAF",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"36a9ca",
"class":"cell txt l",
"children":[
"Nausea; more weight gain than TDF; less kidney and bone toxicity than TDF"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"346d49",
"class":"cell txt l",
"children":[
"Zidovudine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c2819b",
"class":"cell txt l",
"children":[
"Nausea, headache, anemia",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
", leukopenia",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
", lactic acidosis",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
", lipodystrophy, myopathy",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"abf1d7",
"class":"cell txt l",
"children":[
"Nonnucleoside RTIs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a23a5f",
"class":"cell txt l",
"children":[
"Efavirenz"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bb077c",
"class":"cell txt l",
"children":[
"Neuropsychiatric symptoms (dizziness, somnolence, sleep disturbance, vivid dreams, mood changes), rash, dyslipidemia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6ad7ae",
"class":"cell txt l",
"children":[
"Etravirine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ffbcf1",
"class":"cell txt l",
"children":[
"Nausea, rash"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bda66d",
"class":"cell txt l",
"children":[
"Nevirapine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c740be",
"class":"cell txt l",
"children":[
"Hypersensitivity",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
", rash, hepatitis",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"549467",
"class":"cell txt l",
"children":[
"Rilpivirine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a314fb",
"class":"cell txt l",
"children":[
"Rash, headache, insomnia; requires food and gastric acid (no concomitant PPI use) for absorption"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8baf0b",
"class":"cell txt l",
"children":[
"Doravirine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64c683",
"class":"cell txt l",
"children":[
"Nausea, headache"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c2b382",
"class":"cell txt l",
"children":[
"Protease inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10da03",
"class":"cell txt l",
"children":[
"Atazanavir"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8d794a",
"class":"cell txt l",
"children":[
"Nausea, hyperbilirubinemia, nephrolithiasis, rash; requires food and gastric acid (no concomitant PPI use) for absorption"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"664da8",
"class":"cell txt l",
"children":[
"Darunavir"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0d2d49",
"class":"cell txt l",
"children":[
"Nausea, diarrhea, rash"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6436a0",
"class":"cell txt l",
"children":[
"Lopinavir"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4f86bd",
"class":"cell txt l",
"children":[
"Nausea, diarrhea, hyperlipidemia, insulin resistance"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"32ee4c",
"class":"cell txt l",
"children":[
"CCR5 antagonist"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"77c538",
"class":"cell txt l",
"children":[
"Maraviroc"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef1bda",
"class":"cell txt l",
"children":[
"Hypersensitivity, hepatitis",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9f896",
"class":"cell txt l",
"children":[
"Integrase inhibitors",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9b0f8",
"class":"cell txt l",
"children":[
"Dolutegravir",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"239039",
"class":"cell txt l",
"children":[
"Elevated creatinine level (decrease in tubular secretion, not GFR), insomnia, headache (generally well tolerated)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f48085",
"class":"cell txt l",
"children":[
"Elvitegravir"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ac2df2",
"class":"cell txt l",
"children":[
"Nausea, diarrhea (generally well tolerated)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5d888f",
"class":"cell txt l",
"children":[
"Raltegravir"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e94e42",
"class":"cell txt l",
"children":[
"Rash, myopathy (generally well tolerated)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eaf6ba",
"class":"cell txt l",
"children":[
"Bictegravir",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"f"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8f7f9",
"class":"cell txt l",
"children":[
"Elevated creatinine level (decrease in tubular secretion, not GFR), nausea, diarrhea, headache (generally well tolerated)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3f5c90",
"class":"cell txt l",
"children":[
"Pharmacokinetic boosters"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8855f3",
"class":"cell txt l",
"children":[
"Cobicistat"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0de32c",
"class":"cell txt l",
"children":[
"Elevated creatinine level (decrease in tubular creatinine secretion, not GFR), not recommended if CrCl <70 mL/min"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7dc4e4",
"class":"cell txt l",
"children":[
"Ritonavir"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d945c1",
"class":"cell txt l",
"children":[
"Nausea, diarrhea, hyperlipidemia, insulin resistance, lipodystrophy, drug interactions",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CrCl = creatinine clearance; GFR = glomerular filtration rate; HBV = hepatitis B virus; PPI = proton pump inhibitor; RTIs = reverse transcriptase inhibitors; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Many agents are also available as components of combination medications."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Black box warning. Note that all nucleoside analogues have a black box warning about possible lactic acidosis, although it is far more likely with stavudine, didanosine, and zidovudine than the other agents."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"TAF is not recommended in pregnant women because of insufficient safety data."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Integrase inhibitors are associated with more weight gain than other antiretroviral classes."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
},
"Dolutegravir may be used as an alternative antiretroviral drug for women of childbearing age who are sexually active and not using contraception; it may be used as a recommended option for those using effective contraception."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"f"
]
},
"Insufficient safety data exist regarding bictegravir around the time of conception or in pregnant women."
]
]
},
"mk19_a_id_t66":{
"id":"mk19_a_id_t66",
"number":66,
"bookId":"id",
"title":{
"__html":"Recommended Regimens for Initial Treatment of Most Persons with HIV Infection<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"326c9b",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 66. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t66"
}
]
},
"Recommended Regimens for Initial Treatment of Most Persons with HIV Infection",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"60a958",
"class":"cell txt l",
"children":[
"ART can be initiated before drug resistance testing and HLA-B*57:01 test results are available. In this setting, one of the following antiretroviral therapy regimens is recommended:"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5e41e5",
"class":"cell txt li",
"children":[
"Bictegravir/tenofovir alafenamide/emtricitabine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"43d0dc",
"class":"cell txt li",
"children":[
"Dolutegravir with tenofovir",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
" plus emtricitabine or lamivudine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b0615c",
"class":"cell txt l",
"children":[
"Additional recommended regimens include:"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"57088e",
"class":"cell txt li",
"children":[
"Dolutegravir/abacavir/lamivudine",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e0414",
"class":"cell txt li",
"children":[
"Dolutegravir/lamivudine",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b9d994",
"class":"cell txt li",
"children":[
"Raltegravir plus (emtricitabine or lamivudine) plus tenofovir",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Revised based on the 2018 International Antiviral Society–USA Panel guidelines and the 2019 Department of Health and Human Services guideline update. A sample for genotypic testing should be sent before ART initiation. Before initiating treatment in a person of childbearing potential, a pregnancy test should be performed. Before prescribing ART to a person of childbearing potential, please refer to the guideline for information (",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://clinicalinfo.hiv.gov/en/guidelines",
"target":"_blank"
},
"children":[
"https://clinicalinfo.hiv.gov/en/guidelines"
]
},
")."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are two forms of tenofovir that are approved in the United States. TAF has fewer bone and kidney toxicities than TDF, whereas TDF is associated with lower lipid levels. Safety, cost, and accessibility are among the factors to consider when choosing between these drugs."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Only for patients who are HLA-B*57:01 negative and without hepatitis B virus coinfection (AI)."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Except in those with a pretreatment HIV RNA level >500,000 copies/mL, chronic hepatitis B virus coinfection, or before results of HIV genotyping are available."
]
]
}
}
}